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Hepatocellular carcinoma (HCC) is one of the most common
malignant tumours worldwide (Bosch, 1997). It has a well-defined
etiology and develops almost exclusively in patients with chronic
liver damage due to chronic viral infections (hepatitis B and C),
metabolic liver diseases (e.g. haemochromatosis), and toxins
(alcohol, aflatoxin B1) (Schirmacher and Dienes, 1999). Typically
its development encompasses several decades and requires several
genetic and/or epigenetic alterations to occur in affected hepato-
cytes in order to complete malignant transformation, but the
responsible molecular changes are only rudimentarily known. 
Present data suggest a frequent involvement of p53 mutations
(Bressac et al, 1991; Hsu et al, 1991) as well as functional RB-1
deletions in human HCCs (Nishida et al, 1992; Murakami et al,
1991; Walker et al, 1991). Furthermore, evidence for a tumour
suppressor function of the insulin-like growth factor (IGF)-II
receptor in liver tumourigenesis has accumulated (Yamada et al,
1997). Growth factors, like IGF-II and transforming growth factor
(TGF)-α , are known to be frequently overexpressed and support
growth in an autocrine manner in HCCs (Derynck et al, 1987;
Schirmacher et al, 1992; Nong et al, 1997), while the tumorigenic
role of proto-oncogenes is poorly characterized. So far MYC over-
expression and ras-gene mutations appear to be rather infrequent
in human HCCs (Geissler and Gesien, 1997), in contrast to some
well-characterized animal models (Sinha et al, 1988; Fourel et al,
1990; McMahon et al, 1990). Recently oncogenic mutations 
of the β -catenin gene have been found in 26% of human HCCs 
(de la Coste et al, 1998). Altogether, these data have established
the relevance of several tumour genes and suggest that a number of
alterations in different classes of genes are required to complete
the process of hepatocarcinogenesis. The data are nevertheless
biased, since they are derived from selected expression analyses.
Thus there is a need for a largely unbiased screening to detect
genetic events so far not connected with HCC development.
Previous studies using loss of heterozygosity (LOH) analyses
(Tsuda et al, 1990; Nishida et al, 1992; Tsuda et al, 1992; Nagai
et al, 1997) were restricted by the selection of LOH markers and
the fact that by this technique only the detection of potential
tumour suppressor gene loci is feasible. Furthermore data from
LOH analyses in HCCs vary significantly between the different
studies; the resulting LOHs are widely distributed throughout the
genome and have therefore not contributed significantly to the
identification of tumour-relevant genes. 
We have analysed well-characterized HCCs by comparative
genomic hybridization (CGH) and have performed database
analyses to search for potential tumour-relevant genes so far not
linked to hepatocarcinogenesis encompassing the identified
altered chromosomal regions. Our data show frequent gains of
genomic material in chromosomes 1q, 8q, 17q and 20q as well as
losses in 4q, 6q, 13q and 16q, and suggest that genes located in
these chromosomal regions contribute to hepatocarcinogenesis. 
MATERIAL AND METHODS 
Tissues and cell lines 
Tissues were removed by surgery, partly fixed in formalin 
and partly frozen immediately, and stored in pieces of less than 
1c m 3 at –70˚C. Tumours were histologically characterized using
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BJOC 01-1963 697-704  20/8/01  3:24 pm  Page 697representative 2 µ m sections obtained from formalin-fixed,
paraffin-embedded tissues. Tissues used for DNA extraction and
subsequent CGH analyses were especially controlled for
containing more than 90% tumour tissue and the lack of significant
necroses or preservation artifacts by histological analysis of corre-
sponding frozen sections. Grading of HCCs was performed as
recommended by the World Health Organization (WHO) UICC
(Ishak et al, 1994). 
Cell lines HEP-3B, HEP-G2, and SK-HEP1 were purchased
directly from the Deutsche Sammlung für Mikroorganismen und
Zellkulturen (Braunschweig, Germany) and were stored and
cultured as suggested by the supplier. 
DNA-extraction and CGH 
Genomic DNA was obtained from frozen tissues (tumours), cell
lines or peripheral blood cells of normal persons (reference DNA)
by phenol/chloroform extraction according to a standard protocol
(Sambrook et al, 1989). The quality of genomic DNA was
controlled by submitting unrestricted aliquots to 1% agarose gel
electrophoresis prior to the labelling reaction. 
For chromosomal metaphase preparations, peripheral blood
lymphocytes were obtained from normal persons, cultured 
and stimulated with phytohaemagglutinin (1.5%; Gibco BRL,
Eggenstein, Germany) in McCoy’s 5A medium (Gibco BRL). After
culturing for 72 h, metaphase arrest was performed with colcemid
(0.3 µ g/ml; Gibco BRL). All further preparations were performed
according to a standard protocol (Vogel and Speit, 1985). 
CGH was performed according to Lichter et al (1994) with
slight modifications. Slides containing the prepared metaphases
were rehydrated in graded ethanol, 0.1 × standard saline citrate
(SSC), and 2 × SSC, subsequently heat stabilized in 2 × SSC at
75˚C for 30 min, denatured in 0.07 N NaOH and dehydrated in
graded ethanol. Test and reference DNAs were labelled by nick
translation (CGH-nick translation kit; Vysis, Downers Grove, IL,
USA). Hybridization on chromosomal metaphase preparations
was carried out at 37˚C (low stringency) or 55˚C (high stringency)
for 3 d. After the hybridization reaction the slides were washed in
2 × SSC and 2 × SSC Tween 20 at room temperature and 1 × SSC
at 75˚C. 
The ratio profiles of each individual chromosome were deter-
mined using a cytovision 3.1 software (Applied Imaging,
Sunderland, UK). A FITC/TRITC ratio ranging from 0.75–1.25
indicated balanced genomic material (Du Manoir et al, 1995). In
most cases the complete hybridization reaction and analyses were
performed twice, under low (37˚C), and high stringency (55˚C)
hybridization conditions, and only those imbalances of genomic
material reproducible under both conditions were accepted.
Chromosomal regions showing significant frequencies of genomic
alterations were searched for potential tumour-relevant 
genes using the OMIM-NCBI database (www.ncbi.nlm.nih.gov/
omim/searchmap.html), which is currently estimated to contain
more than half of the expected human genes annotated by chromo-
somal localization (Deloukas et al, 1998). The current analysis
focussed on chromosomal regions that were frequently altered in
the CGH analysis. These chromosomal regions that were screened
for those genes that either had an already established or suspected
function in human hepatocarcinogenesis or a known oncogenic or
tumour-suppressive function, matched to the respective type of
genomic imbalance and were likely to act in carcinoma cells
(Figure 1). 
Interphase fluorescence in situ hybridization (FISH) 
Interphase FISH was performed in selected representative 
cases (3) with a limited number of frequently occurring genomic
imbalances in order to confirm the results of the CGH analysis.
Isolated interphase nuclei were obtained according to Hopman 
et al (1992) except that fixation was performed in methanol/acetic
acid (3:1). Hybridization reactions were performed with CEP- and
LSI-DNA FISH probes (Vysis). Fluorescence microscopy and
photomicroscopy were performed with a Leica DMRBE micro-
scope (Leica, Bensheim, Germany). Hybridization was carried out
simultaneously with a test probe directed against a chromosomal
region showing genomic imbalance (1q: 1q12 (sat. II and III); 
8: 8p11.1-q11.1 (α -sat. DNA); 13q: 13q14 (RB-1 locus)) and a
reference probe derived from a region without significant alter-
ation according to the respective CGH ratio profile (10p11.1-q11.1
(α -sat. DNA); 17p11.1-q11.1 (α -sat. DNA)). In each analysis
more than 100 interphase nuclei were evaluated by fluorescence
microscopy. The number of signals per nucleus were counted for
each probe. Then the ratio of test probe signal/reference probe
signal was determined for each signal interphase nucleus. The
nuclei were then grouped according to this signal ratio. 
cDNA-arrays 
cDNA expression analysis was performed in tumour No. 6
containing the frequently occurring gains of genomic material at
1q and 8q (as well as X) in order to test in an unbiased manner
whether the genomic imbalances were associated with alterations
in expression of genes located in these chromosomal regions.
Atlas Human cDNA Expression Arrays (Clontech, Palo Alto, CA,
USA) were performed as recommended by the supplier. 
Filter analysis and semiquantitative evaluation was performed
with a Storm 840 phosphofluoroimager (Molecular Dynamics,
Sunnyvale, CA, USA) using the Image QuaNT software (version
5.0; Molecular Dynamics). 
RESULTS 
All HCCs that were analysed met the histological pre-evaluation
criteria and resulted in well-interpretable metaphases and CGH
ratio profiles. In all HCCs and cell lines with the exception of 3
HCCs, significant genomic imbalances were detected (Table 1).
All cell lines showed a rather high number of genomic imbalances. 
In tumour No. 6, the CGH ratio profiles showed a gain of 1q and
an amplification of 8q. In FISH analyses of isolated interphase
HCC nuclei with centromeric probes from both chromosomes,
significant numerical over-representations of the hybridization
signals for each of the test probes were detectable compared to the
reference probes (Figure 1A and B, Table 2).
In tumour No. 8, among other alterations, a significant loss of
13q encompassing 13q14.1-14.2, the location of the RB-1 gene was
found. Here interphase FISH also detected under-representation of
13q14.1-14.2 using a RB-1 locus-specific probe compared to a
control probe from the centromeric region of chromosome 10 that
appeared unaltered in the CGH ratio profile (Figure 2c, Table 2) 
Overall gains of genomic material outnumbered losses in
frequency (Table 1). When the genomic imbalances were sorted by
chromosomal location (Figure 1, Table 1B), gains were most
frequently detected in: 1q (57%, core region: 1q21-24), 8q (52%,
core region: 8q24.1-24.3), 17q (29%) and 20q (29%). Losses were
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BJOC 01-1963 697-704  20/8/01  3:24 pm  Page 698less frequent but significantly altered regions were present in 4q
(33%, core region: 4q22-28), 6q (19%), 13q (19%), and 16q
(14%). The same alterations were also in part represented in the 3
analysed cell lines. There was no indication for certain genomic
CGH analysis of HCC 699
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Figure 1 Summarized display of genomic imbalances detected in 21 HCCs. (above) Gains of genomic material are shown on the right side; losses are shown
on the left side of each chromosome, corresponding to the respective chromosomal regions. Intensity of the lines corresponds to the extent of gains (thin line:
ratio of 1.25–1.5, thick line > 1.5). Data correspond to Table 1. (below) Localization of significant gains and losses of genomic material. Chromosomal areas with
significant genomic imbalances are shown as boxes with gains located to the right and losses located to the left of the respective chromosomal region.
Consensus core regions are shown as black boxes. The location of some potential tumour-relevant genes in these areas is shown (see Discussion)
BJOC 01-1963 697-704  20/8/01  3:25 pm  Page 699imbalances to co-segregate. There was no correlation of the most
frequent imbalances (gains of 1q and 8q and losses of 4q and 13q)
compared to the grade of tumour differentiation, with the exception of
13q losses that were not detected in highly differentiated (G1) HCCs. 
Since gains of genomic material may correlate with activated
oncogenes and losses with the inactivation of tumour suppressor
genes, a database analysis (OMIM-NCBI) was performed in order
to identify known genes with potential relevance for the tumori-
genic process located in these chromosomal regions. A number of
genes of specific interest in the context of HCC that were identi-
fied by this search are shown in Figure 1. 
To further analyse the potential consequences of genomic
imbalances on gene expression, cDNA array analyses (Clontech)
were performed with tumourous and non-tumourous liver RNA
from tumour No. 6 (with 1q; 8q and X gains). Of the 518 genes
evaluated, 126 genes showed significantly altered (> 3-fold)
expression composed to the non-tumourous liver tissue; of those, 8
genes located in these chromosomal regions showed significant
700 F Niketeghad et al 
British Journal of Cancer (2001) 85(5), 697–704 © 2001 Cancer Research Campaign
Table 1 Genomic imbalances in HCCs and liver tumor cell lines. (A) Listing of cases; (B) Summary 
A
No. Sex G Etiology Gains Losses 
1 m G1 HBV 1q, 2, 5p, 5q, 6p, 7p21-22, 7q,  3p, 6q, 12q15-24.3, 21q21-22 
8q21.1-21.3, 13q31-34, 17p
2 m G2 ethanol 1q12-25, 1p, 2p, 3q, 6p11-21.2, 9p,  3p, 4q, 6q31-34, 8p, 9q, 10q
17q, 19q12-13.2, 20q, Xq22-26  22-26, 13q, 16q, 20p, Y 
3 m G2 HBV ––  
4 f G2-3 hemochrom. 8q24.2-24.3, 11q12-14 4q 
5mG 1 Ø 8q11.1-36, 15p, 15q11.1-12, 22p, 22q – 
6mG 1 Ø 1q, 8q21.1-24.3, Xp, Xq21-28 – 
7 m G3 HBV 1q – 
8 m G3 ethanol 1q, 1p33-11, 4p16-14, 15q13-22, 17q 4q24-25, 11q24-25, 13q, 14q33, 21q, Yq 
9 m G2 ethanol 1q – 
10 f G1 Ø– –  
11 m G1 Ø 14p13-q12, 15p13-q13 – 
12 m G1 HBV 7p, Xq 4q, 5p15.1-15.3, 5q11.2-21, 10q, 16q12.1-23 
13 m G1 Ø 1q11-31, 17q 16q23-24 
14 m G2 HBV 1q, 6, 8q, 11p15, 13q33-34,  8p2-23, Y 
14q32, 15q11.2-15, 21
15 m G2-3 HBV 8q Y 
16 m G2 ethanol ––  
17 m G3 Ø 1p, 1q11-33, 3p11-14 3q, 4p, 6p12- 3p22-26, 4q13-35, 6q13-27, 
21.3, 8q12-24.1, 12q, 17q, 20 13q, 14q, Y11.2 
18 f G1 Ø 1q12-32, 3, 5p, 5q11.1-14, 6p, 7p12- 4q, 11, 12p12-13, 16q21-24 
15, 8, 9q11-21, 17q, 18, 20, X
19 m G2 HBV 8q, 17q21-25, 20q13.2-13.3 Yq 
20 m G2 HBV 1q12-41, 6, 7p, 8q13-24.1, 20 4q, 8p, 12p, Y11.2 
21 f G2-3 Ø 1q, 2q32-37, 7p14-22, 8q,  4p16, 4q22-28, 6q, 10q25-26, 13p, 
12q21-24.1, 13q31-34, 20q 13q11-14, 16p12-13.3, 21q, 22, X 
* HEP-3B 1q, 3q21.6-29, 4p, 6p, 7p,  4q24-q 35, 5q14-q23, 13q14-q22, Y 
11p, 13qter, 19p, 20q
*SK-HEP1 6p, 17 4, 6q, 9, 18q12-23, Y 
*HEP-G2 2, 6p, 16p, 16q, 17q, 19p, 20 13q14-22 
*: cell line; G: grade; Ø: no defined etiology (HBV and haemochromatosis negative). 
B
No. of cases % Genomic imbalance 
Gains 12 57 1q (core region: 1q12-25) 
11 52 8q (core region: 8q21.2-24.3) 
6 29 17q (core region: 17q21.3-25) 
62 9 2 0 q  
5 24 7p 
Losses 7 33 4q (core region:4q22-28) 
4 19 13q (core region:13q12-14) 
4 19 6q 
31 4 1 6 q  
BJOC 01-1963 697-704  20/8/01  3:25 pm  Page 700overexpression in the tumour RNA (Table 3), among them the
protooncogene c-ski. 
DISCUSSION 
The present CGH study of human HCCs has identified a number of
prominent genomic imbalances (Table 1 and Figure 1) that were
selectively confirmed by FISH analyses of the respective inter-
phase HCC nuclei. Our data show in part a correlation with one
previous analysis (Marchio et al, 1997), although significant
differences to this study exist. The overall percentage of genomic
imbalances in our material is lower, which may be due to differ-
ences in case selection, not limited to HBV-induced HCCs in our
study, but more likely to the stringent criteria applied to the accep-
tance of genomic imbalances in the present study. Some of the
previously reported alterations (1p del, 4p del, 17p del, 19q amp,
and X del) were not detected or did not reach significance in our
analysis. In contrast there is a good match in the type of genomic
imbalances of our study to a second, recent one (Wong et al, 1999)
although the percentage of imbalances in our study is slightly but
consistently lower for each single type of imbalance. It can there-
fore be speculated that the extent and type of genomic imbalances
may be influenced by the underlying etiology of HCC. 
Significant gains of genomic material have been found at 1q, 8q,
17q and 20q. These alterations appear to be selected and main-
tained during hepatocarcinogenesis and thus represent candidate
regions for relevant proto-oncogenes or growth-promoting genes.
Since 1q and 8q gains and 4q losses are detectable in highly and
poorly differentiated tumours at an almost equal frequency, there is
no evidence for a correlation with tumour cell differentiation. In
the core region of 1q, the retinoic acid receptor gamma gene is
located (1q22-23) that was originally cloned from an HCC and
which is frequently overexpressed in HCCs (de The et al, 1987;
Benbrook et al, 1988). Furthermore the c-myc gene (as well as the
myc-activator) is located in 8q24, and is known to be activated in
HCC cells (Huber and Thorgeirsson, 1987). The functional rele-
vance of its overexpression due to genomic amplification is well
documented (Koskinen and Alitalo, 1993). Correlative cDNA
microarray expression screening in tumour No. 6 that showed gain
CGH analysis of HCC 701
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Table 2 Interphase FISH analysis 
Tumour No. Probes test/reference Q ≤ 0.5 (%) 1 > Q > 0.5 (%) Q = 1 (%) Q > 1 (%) 
8 13/10 83.3 10.2 5.6 0.9 
(13q14(RB-1) / 10p11.1-q11.1 (α -sat. DNA)) 
6
1/17 0 1.9 30.7 67.3 
(1q12 (sat. II and III) / chr.17p11.1-q11.1 (α -sat. DNA)) 
8/10 1.8 10.7 40.2 47.3 
(8p11.1-q11.1 (α -sat. DNA) / 10p11.1- q11.1 (α -sat. DNA)) 
Q: ratio of the numbers of signals per nucleus using the 2 indicated hybridization probes. 
A
B
C
Figure 2 Representative interphase FISH analyses in tumour Nos 6 and 8.
(A) Interphase FISH with a satellite-DNA centromeric probe specific for
chromosome 1 (red) and a satellite-DNA centromeric probe for chromosome
17 (green) (tumour No. 6). (B) Interphase FISH with a satellite-DNA-probe
specific for chromosome 8 (green) and a satellite-DNA-probe specific for
chromosome 10 (red) (tumour No. 6). (C) Interphase FISH with a LSI-probe
for 13q14 covering the RB-1 gene (green) and a satellite-DNA-probe for
chromosome 10 (red) (tumour No. 8). 
BJOC 01-1963 697-704  20/8/01  3:25 pm  Page 701of 1q and 8q (see Table 1) has identified a number of genes that are
highly overexpressed in the tumour tissue and are located in these
chromosomal regions: (1q: SKI, 8q: SII ) compared to the non-
tumourous liver, suggesting that at least for some genes gains of
genomic material may support overexpression. SKI appears
particularly to be activated by overexpression and to represent a
potential target gene since it has been recently shown to suppress
transcriptional repression exerted by the Smad-mediated TGF-β
activated pathway (Sun et al, 1999). This growth-suppressive
pathway is deactivated at least in a wide variety of malignant
epithelial tumours (Hata et al, 1998). 
In 4 cases, deletions encompass 13q, a chromosomal region that
contains not only the RB-1 (13q14.1-14.2), but also the BRCA-2
(13q12.3) gene. LOHs in 13q are relatively frequent in HCCs (up to
49%) and additionally sequence abnormalities in the RB-1 gene have
been detected in up to 25% of HCCs (Murakami et al, 1991). Loss of
function of the BRCA-2 gene has so far not been described in HCCs,
but beside its well-documented role in breast cancer (Wooster et al,
1994, 1995), it also occurs in sporadic cancer of the exocrine
pancreas (Schutte et al, 1995; Teng et al, 1996), an organ with its
cellular origin embryologically closely related to hepatic tissue. 
There are 3 cases that show deletions of 16q, which contain the
cadherin gene cluster including E-cadherin at 16q22.1. Loss of E-
cadherin expression has been linked to the gain of invasive poten-
tial (Frixen et al, 1991; Vleminckx et al, 1991; Berx et al, 1995)
and has recently been identified as the cause of hereditary gastric
cancer (Guilford et al, 1998). LOHs at 16q have on one hand been
observed in 40–70% of the cases in HCC studies (Nishida et al,
1992; Yeh et al, 1996) but have conversely been correlated with
advanced stages (Nishida et al, 1992) and dedifferentiated
morphology of HCC (Shimoyama and Hirohashi, 1991).
Functional inactivation of E-cadherin in carcinomas may addition-
ally arise epigenetically through hypermethylation (Graff et al,
1995). Interestingly the Fanconi anemia gene is also located at
16q24.3 (Gschwend et al, 1996), and it may be hypothesized that
in addition to loss of E-cadherin expression, somatic activation of
a chromosomal breakage phenotype may support HCC progres-
sion. Another chromosomal breakage syndrome, ataxia teleangiec-
tasia, may carry a slightly increased risk of hepatocellular
carcinoma (Weinstein et al, 1985). 
Chromosomal macrodeletions were most frequently found in
4q. A tumour-suppressor gene relevant for HCC development has
already been suspected at this location from several LOH studies
(frequency: 17–77%) (Buetow et al, 1989; Zhang et al, 1990;
Konishi et al, 1993; Yeh et al, 1996; Chou et al, 1998). A common
chromosomal breakpoint mapped to 4q has also been found in 4
out of 50 HCCs (Pasquinelli et al, 1988) as well as an HBV inte-
gration site in an HCC at 4q32.1. Furthermore caspase genes
(caspase-6 (4q25), caspase-3 (4q35)) and the smad1 gene (4q28)
are located at 4q. Nevertheless a definite target tumour-suppressor
gene at 4q has so far not been identified. 
In contrast other LOHs frequently observed at 17p (up to 64%),
1p (30–83%) and 11p (up to 44%) did not correlate with losses of
genomic material in our CGH analysis and are thus unlikely to
result from macrodeletions. Thus macrodeletions were not found
to encompass the p53 locus at 17p13.1, in consistence with the fact
that frequently the loss of p53 function in HCCs is due to point
mutations at codon 249 (Fujimoto et al, 1994; Bressac et al, 1991),
and not to deletions as described for glioblastomas (Albertoni et al,
1998). Furthermore no significant gains of genomic material have
been found at chromosomal locations of growth factors that are
frequently overexpressed in HCCs, such as IGF-II (11p15.5) and
TGFα (2p13), suggesting that genomic amplification is a rather
unlikely cause of growth factor overexpression in HCCs. 
In conclusion, our CGH analysis of HCCs induces several
hypotheses regarding activated or suppressed genes relevant to
hepatocarcinogenesis. Some of them (RB-1 and E-cadherin) are
reflected by preliminary expression data but many more including
the ones mentioned events (Figure 1) will have to be tested by
appropriate expression analyses. 
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